Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the LIBERATE study

被引：0

作者：

Reich, Kristian ^{[1
]}

Goodfield, Mark ^{[2
]}

Green, Lawrence ^{[3
]}

Nograles, Kristine ^{[4
]}

Chen, Rongdean ^{[4
]}

Levi, Eugenia ^{[4
]}

机构：

[1] Dermatologikum Hamburg, Hamburg, Germany

[2] Leeds Gen Infirmary, Leeds, W Yorkshire, England

[3] George Washington Univ, Sch Med, Washington, DC 20052 USA

[4] Celgene Corp, Summit, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

5436

引用

页码：AB224 / AB224

页数：1

共 50 条

[1] SAFETY AND EFFICACY OF APREMILAST THROUGH 104 WEEKS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS WHO CONTINUED ON APREMILAST OR SWITCHED FROM ETANERCEPT TREATMENT IN THE LIBERATE STUDY
Reich, K.
Goodfield, M.
Green, L.
Nograles, K.
Chen, R.
Levi, E.
Langley, R. G. B.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1325 - 1326
[2] Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
Reich, K.
Gooderham, M.
Bewley, A.
Green, L.
Soung, J.
Petric, R.
Marcsisin, J.
Cirulli, J.
Chen, R.
Piguet, V.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 397 - 402
[3] LIBERATE trial: sustained efficacy of apremilast in patients with moderate-to-severe psoriasis who continued on apremilast or switched from etanercept treatment
Reich, K.
Soung, J.
Gooderham, M.
Zhang, Z.
Nograles, K.
Goodfield, M.
BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 71 - 72
[4] Efficacy of apremilast sustained through week 52 in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: results from the liberate study
Reich, K.
Papp, K.
van de Kerkhof, P.
Zhang, Z.
Nograles, K.
Soung, J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 68 - 68
[5] Sustained efficacy of apremilast in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: 52-week results from the LIBERATE study
Reich, Kristian
Soung, Jennifer
Gooderham, Melinda
Zhang, Zuoshun
Nograles, Kristine
Goodfield, Mark
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB276 - AB276
[6] 52-Week efficacy in patients with moderate to severe psoriasis continued on apremilast or switched from etanercept: The LIBERATE study
Reich, K.
Papp, K.
van de Kerkhof, P.
Zhang, Z.
Nograles, K.
Soung, J.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 69 - 70
[7] Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study
Reich, Kristian
Goodfield, Mark
Green, Lawrence
Nograles, Kristine
Chen, Rongdean
Levi, Eugenia
Langley, Richard G. B.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[8] Sustained efficacy with apremilast in patients with nail and scalp psoriasis who continued on apremilast or switched from etanercept treatment: 52-week results from the LIBERATE study
Gooderham, Melinda
Zhang, Zuoshun
Day, Robert
Ferris, Laura
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB277 - AB277
[9] Sustained efficacy with apremilast in patients with nail and scalp psoriasis who continued on apremilast or switched from etanercept treatment: 52-week results from the liberate study
Gooderham, M.
Zhang, Z.
Day, R.
Ferris, L.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 66 - 67
[10] 52-WEEK EFFICACY AND SAFETY OF APREMILAST AND SWITCH FROM ETANERCEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS FROM THE LIBERATE STUDY
Reich, K.
Soung, J.
Gooderham, M.
Zhang, Z.
Nograles, K.
Day, R. M.
Ferris, L.
Goodfield, M.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 349 - 349

← 1 2 3 4 5 →